Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
INTEGRILIN |
| Manufacturer |
|
Schering Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antiplatelet (GP IIb/IIIa blocker). |
| Generic Name |
|
Eptifibatide 0.75mg/mL, 2mg/mL; soln for IV inj. |
| Indications |
|
For acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting. |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Use in combination with aspirin and heparin. ACS: 180micrograms/kg IV bolus, followed by a continuous IV infusion of 2micrograms/kg/min until discharge or CABG surgery, up to 72 hours. If PCI planned, continue infusion until discharge, or for up to 18–24hrs after procedure, whichever comes first, allowing up to 96hrs of therapy. PCI: 180micrograms/kg IV bolus followed by 2micrograms/kg/min infusion; repeat 180micrograms/kg IV bolus 10minutes after the 1st bolus; continue infusion until discharge, or for up to 18–24hrs, whichever comes first, minimum 12hr-infusion recommended. CrCl <50mL/min: reduce infusion rate to 1microgram/kg/min. |
| Contraindications |
|
Bleeding diathesis or active abnormal bleeding within previous 30 days. Severe uncontrolled hypertension. Major surgery within previous 6 weeks. History of stroke within 30 days or any history of hemorrhagic stroke. Concomitant parenteral GP IIb/IIIa inhibitors. Renal dialysis. |
| Precautions |
|
See literature. Discontinue if uncontrolled bleeding occurs. Platelet count <100,000/mm3. Properly care for femoral artery access site to minimize bleeding. Minimize other arterial and venous punctures, IM inj, catheter use, intubation, NG tubes, to lower bleeding risk; avoid use of non-compressible IV access sites. Do baseline platelet counts, hemoglobin, hematocrit, others and monitor during therapy (see literature). Discontinue if confirmed thrombocytopenia occurs. Renal insufficiency. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
Antiplatelet effects may be potentiated by thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole. |
| Adverse Reactions |
|
Bleeding, intracranial hemorrhage, stroke, thrombocytopenia, hypersensitivity reactions, hypotension. |
| How Supplied |
Vial 0.75mg/mL (100mL)—1
2mg/mL (10mL, 100mL)—1 |
|
|
|
|
